Phoenix IVBM Spotlights Oncology Innovation, Access Barriers, and Partnerships

Why It Matters

These operational insights identify levers to accelerate innovative oncology care to broader patient populations, directly impacting outcomes and health‑system costs.

Key Takeaways

• Community oncology can adopt new drugs faster than health‑system pipelines.
• Medicare and payer delays stall breast‑cancer molecular testing and treatment.
• Early CAR‑T therapy preferred over bispecifics for fit multiple myeloma patients.
• Autologous transplant still central, delivering >10‑year survival in many cases.
• Outpatient bispecific antibody programs need new monitoring for CRS/ICANS.

Pulse Analysis

Value‑based oncology hinges on aligning academic breakthroughs with community practice realities. The IVBM conference underscored that private‑practice models often bypass lengthy health‑system IT builds, enabling quicker access to newly approved agents. Yet, fragmented pathology services and rigid Medicare guidelines create bottlenecks that delay critical molecular profiling, especially in breast cancer. Understanding these workflow gaps allows health systems to redesign contracts, invest in shared‑service labs, and negotiate payer pathways that keep pace with rapid drug development.

Breast‑cancer care illustrates the tension between scientific progress and reimbursement lag. Emerging agents such as camizestrant show promising progression‑free survival, but without clear guideline endorsement, payers frequently demand extensive justification, extending approval timelines by months. Clinicians highlighted real‑world cases where delayed molecular testing left patients in therapeutic limbo. Strategies that streamline pathology turnaround—centralized staining hubs, digital slide review, and pre‑authorization frameworks—can mitigate these delays, ensuring patients receive the most effective, personalized regimens without unnecessary waiting periods.

In multiple myeloma, the treatment algorithm is evolving toward a hybrid model that preserves the proven survival benefit of autologous transplant while integrating cellular therapies earlier. Experts at the summit argued that fit patients should receive CAR‑T in the second line to maximize durability, reserving bispecific antibodies for later stages to avoid compromising CAR‑T efficacy. Simultaneously, the shift of bispecific and CAR‑T administration to outpatient settings demands robust monitoring protocols for CRS and ICANS, as well as staff training. Health systems that invest in these capabilities will not only improve patient convenience but also reduce inpatient costs, positioning themselves at the forefront of value‑based cancer care.